Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,437 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,348)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03422731 | Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy | active not recruiting | Early Phase 1 | 82 | City of Hope Medical CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT01683279 | A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 | 6 | Seattle Children's HospitalOTHER | 1 | Jun 5, 2026 |
| clinicaltrials |
| NCT03960840 | Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL | active not recruiting | Phase 1 / Phase 2 | 217 | Novartis PharmaceuticalsINDUSTRY | 8 | Jun 4, 2026 | clinicaltrials |
| NCT04722172 | A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL | active not recruiting | Phase 2 | 55 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT02450708 | Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes | active not recruiting | N/A | 511 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT05364762 | Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants | active not recruiting | Phase 2 | 20 | City of Hope Medical CenterOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT00544115 | Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders | active not recruiting | Phase 2 | 260 | City of Hope Medical CenterOTHER | 0 | Jun 2, 2026 | clinicaltrials |
| NCT04128748 | Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome | active not recruiting | Phase 1 / Phase 2 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05146739 | Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane | active not recruiting | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2026 | clinicaltrials |
| NCT03319901 | Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL | active not recruiting | Phase 1 / Phase 2 | 82 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT03330821 | Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 53 | University of Southern CaliforniaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT02091245 | Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML | active not recruiting | Phase 1 | 16 | Dana-Farber Cancer InstituteOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT03157323 | Low GI Diet in Children and Adolescents With ALL | active not recruiting | N/A | 88 | Columbia UniversityOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06092879 | Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France(ASSURE-3) | active not recruiting | — | 201 | Novartis PharmaceuticalsINDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT06445907 | Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia | active not recruiting | Phase 1 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT02275533 | Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial | active not recruiting | Phase 2 | 82 | National Cancer Institute (NCI)NIH | 2 | May 28, 2026 | clinicaltrials |
| NCT05157971 | Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 | 24 | City of Hope Medical CenterOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT01351896 | Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | active not recruiting | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | May 27, 2026 | clinicaltrials |
| NCT02632708 | Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | active not recruiting | Phase 1 | 153 | Institut de Recherches Internationales ServierOTHER | 3 | May 22, 2026 | clinicaltrials |
| NCT03613532 | Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN | active not recruiting | Phase 1 | 102 | Jacqueline Garcia, MDOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT03747757 | Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue | active not recruiting | Phase 2 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05844033 | Biomarker for Infection Risk in CLL and MM | active not recruiting | — | 150 | Massachusetts General HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT04380441 | Quality of Life Model for Older Patients With AML | active not recruiting | — | 206 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT02334865 | SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy | active not recruiting | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT03844048 | An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | active not recruiting | Phase 3 | 165 | AbbVieINDUSTRY | 23 | May 13, 2026 | clinicaltrials |
| NCT04067336 | First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 263 | Kura Oncology, Inc.INDUSTRY | 7 | May 13, 2026 | clinicaltrials |
| NCT04314401 | National Cancer Institute "Cancer Moonshot Biobank" | active not recruiting | — | 1,600 | National Cancer Institute (NCI)NIH | 2 | May 13, 2026 | clinicaltrials |
| NCT06066242 | Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemotherapy | active not recruiting | N/A | 113 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06744556 | HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML | active not recruiting | Phase 2 | 41 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT04150887 | Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia(ELEVATE) | active not recruiting | Phase 1 | 61 | OncoVerity, Inc.INDUSTRY | 5 | May 12, 2026 | clinicaltrials |
| NCT04801797 | Venetoclax + Azacitidine vs. Induction Chemotherapy in AML | active not recruiting | Phase 2 | 172 | Massachusetts General HospitalOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT05088356 | Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft | active not recruiting | Phase 1 | 66 | Stanford UniversityOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT05583552 | Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy(IMpress) | active not recruiting | Phase 2 | 46 | GCP-Service International West GmbHINDUSTRY | 3 | May 12, 2026 | clinicaltrials |
| NCT03286634 | ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016 | active not recruiting | Phase 2 | 60 | National Hospital Organization Nagoya Medical CenterOTHER | 6 | May 11, 2026 | clinicaltrials |
| NCT03770429 | AZD6738 for Patients With Progressive MDS or CMML | active not recruiting | Phase 1 | 52 | Massachusetts General HospitalOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05453500 | Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia | active not recruiting | Phase 2 | 32 | University of WashingtonOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06384261 | A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy | active not recruiting | Phase 2 | 140 | OncoVerity, Inc.INDUSTRY | 5 | May 11, 2026 | clinicaltrials |
| NCT05718869 | Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study | active not recruiting | Phase 2 | 26 | City of Hope Medical CenterOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06323590 | Refining the Role of Mid-induction Bone Marrow Biopsy in Acute Myeloid Leukemia: A Pilot Study | active not recruiting | — | 60 | University of Alabama at BirminghamOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT03984968 | CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 / Phase 2 | 40 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT03560882 | A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies | active not recruiting | Phase 1 | 50 | Joaquina BarandaOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04657094 | Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia | active not recruiting | Phase 2 | 4 | City of Hope Medical CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04872595 | A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant | active not recruiting | Phase 2 | 59 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04872790 | Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia | active not recruiting | Phase 1 | 20 | OHSU Knight Cancer InstituteOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT02029443 | ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia | active not recruiting | Phase 1 / Phase 2 | 306 | Acerta Pharma BVINDUSTRY | 3 | May 5, 2026 | clinicaltrials |
| NCT03821610 | A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)(ALL-RIC) | active not recruiting | Phase 2 | 242 | University of BirminghamOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04217278 | A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT(COSI) | active not recruiting | Phase 2 / Phase 3 | 333 | University of BirminghamOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04482894 | Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS | active not recruiting | N/A | 105 | University of VirginiaOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04493138 | Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations | active not recruiting | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04626024 | Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population(TOKIN) | active not recruiting | Phase 2 | 17 | Baylor College of MedicineOTHER | 1 | May 4, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 8, 2026source: clinicaltrials